Ainnova Tech Ends JV and Reverse-Merger Discussions with Avant Technologies

Houston, Texas & San José, Costa Rica – October 7, 2025 – Ainnova Tech, Inc. (“Ainnova”) announced today that it will not proceed with the previously discussed joint venture or potential reverse merger with Avant Technologies. Following a careful review of the process, counterparty non-fulfillment of certain conditions and timelines, and the fact that both parties were unable to reach an agreement on key terms, Ainnova has decided, amicably and without further delay, not to move forward with the proposed transaction.

Ainnova now has a new strategic opportunity under consideration, which the company is currently evaluating in detail and expects to enter into formal discussions in the near term. This initiative represents a strong strategic fit and significant potential for Ainnova, its partners, and stakeholders.

Meanwhile, Ainnova continues to advance its commercial expansion, strengthening strategic alliances with pharmaceutical companies, primary-care networks, and insurers across Latin America, while pursuing FDA pathway activities in preparation for its entry into the U.S. market. In parallel, the company is preparing the launch of its automated, low-cost retinal camera and has an exploratory agreement in place with one of the world’s largest ophthalmic device companies to assess potential investment and distribution opportunities.

Aligned with these priorities, Ainnova will soon share updates on the progress of this new strategic engagement and related discussions regarding potential access to the public markets, together with the reopening of its joint investment round to support upcoming milestones, including FDA pathway execution, commercial scale-up, and the retinal camera launch, all expected to contribute to significant growth for the company.

About Ainnova Tech

Ainnova Tech is a Nevada-based healthtech startup with headquarters in San José, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team dedicated to leveraging artificial intelligence for early disease detection, Ainnova has received multiple global awards and established renowned partnerships with hospitals and medical device companies.

Through its flagship platform, Vision AI, Ainnova seeks to prevent blindness and detect the early onset of diabetes, Cardiovascular risk, CKD, Liver Fibrosis and other conditions, pioneering a new model of accessible and proactive healthcare. The company continues to expand its AI-driven solutions toward broader disease-risk screening and population-health management.

Forward-Looking Statements

This press release may contain forward-looking statements, including expectations regarding future strategic options, partnerships, transactions, and product launches. These statements involve risks and uncertainties that may cause actual results to differ materially. Ainnova undertakes no obligation to update or revise forward-looking statements except as required by applicable law.

Media Contact
Company Name: Ainnova Tech
Contact Person: Diana Quesada
Email: Send Email
Country: United States
Website: https://ainnovatech.com/